NextPlat (NXPL) Net Income towards Common Stockholders Growth (1y) (2011 - 2026)
Powered by 
Analysis
NextPlat (NXPL) Net Income towards Common Stockholders Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.34 Bn | 38.68 Bn | 2.15 Bn | -304.98% |
| 2 | Viatris | 19.39 Bn | 18.50 Bn | 1.46 Bn | -2,482.61% |
| 3 | Dr Reddys Laboratories | 9.99 Bn | 9.85 Bn | 396.53 Mn | -71.72% |
| 4 | Amneal Pharmaceuticals | 5.57 Bn | 5.53 Bn | 334.51 Mn | 95.49% |
| 5 | Bausch Health Companies | 2.45 Bn | 1.58 Bn | 2.10 Bn | 103.13% |
| 6 | Ani Pharmaceuticals | 1.70 Bn | 1.34 Bn | 165.89 Mn | 203.33% |
| 7 | Alvotech | 1.66 Bn | 1.52 Bn | 2.56 Mn | - |
| 8 | Amphastar Pharmaceuticals | 985.90 Mn | 695.77 Mn | 93.47 Mn | -2.20% |
| 9 | Fennec Pharmaceuticals | 434.07 Mn | 392.82 Mn | 17.15 Mn | 162.60% |
| 10 | NextPlat | 24.77 Mn | 12.93 Mn | 4.69 Mn | 91.95% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 91.95% |
| Mar 31, 2026 | 42.43% |
| Dec 31, 2025 | -164.47% |
| Sep 30, 2025 | 48.17% |
| Jun 30, 2025 | 66.32% |
| Mar 31, 2025 | -31.13% |
| Dec 31, 2024 | -42.40% |
| Sep 30, 2024 | -222.27% |
| Jun 30, 2024 | -22.35% |
| Mar 31, 2024 | -24.77% |
| Dec 31, 2023 | -80.30% |
| Sep 30, 2023 | 160.35% |
| Jun 30, 2023 | -162.16% |
| Mar 31, 2023 | -39.63% |
| Dec 31, 2022 | 73.40% |
| Sep 30, 2022 | -147.81% |
| Jun 30, 2022 | -13.54% |
| Mar 31, 2022 | -3.72% |
| Dec 31, 2021 | -152.06% |
| Sep 30, 2021 | -109.51% |